Mechanistic study on how the Tet1/ARF-p53 pathway affects idiopathic pulmonary fibrosis through macrophage polarization Authors: Peng Zhang, Xiaotong Guo, Ting Wang, Shaojin Wang Published: 2025 ABSTRACT BackgroundThis study aimed to investigate the mechanism by which the Tet1/ARF-p53 pathway affects idiopathic pulmonary fibrosis (IPF) through macrophage polarization.MethodsThe polarization state of macrophages in IPF was analyzed, and the role of the Tet1/ARF-p53 pathway in macrophage polarization was examined. The expression changes of Tet1, ARF, and p53 were detected in both in vitro cell culture and in vivo animal models, as well as the levels of M1 and M2 macrophage markers.ResultsTet1 regulated the DNA methylation status of the ARF gene, thereby affecting ARF expression and subsequently activating the p53 pathway. This regulation affected macrophage polarization, where M2 macrophage polarization was inhibited, ultimately alleviating the progression of pulmonary fibrosis.ConclusionThe Tet1/ARF-p53 pathway plays a role in IPF by regulating macrophage polarization, providing a new potential therapeutic target for IPF.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12967-025-07538-4. Introduction Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible, and fatal lung fibrosis disease of unknown etiology that is associated with aging [1, 2]. It is the most common type of idiopathic interstitial pneumonia and is characterized by diffuse alveolar inflammation, proliferation and transformation of fibroblasts within the lung, expansion of the extracellular matrix, and extensive remodeling of lung parenchyma [3, 4]. The clinical manifestation of IPF includes progressive dyspnea and declining lung function, ultimately leading to respiratory failure and death [5]. The prognosis of IPF is extremely poor, and it responds poorly to corticosteroids and immunosuppressants [6]. Currently, there are no effective treatment options with proven efficacy, making it urgent and crucial to explore new and effective therapeutic strategies for IPF [7]. The pathogenesis of IPF is complex and involves multiple cell types and signaling pathways [8, 9]. Recent studies have found that macrophages play a critical role in the development of pulmonary fibrosis [10]. As key immune regulatory cells, macrophages are central to the inflammatory response and fibrotic processes in IPF [11]. Depending on the microenvironment, they can polarize into M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotypes [12]. The Tet1/ARF-p53 pathway is known to play a role in various cellular processes, including cell cycle regulation, DNA damage response, and apoptosis [13]. This study aimed to explore how the Tet1/ARF-p53 pathway contributes to the progression of IPF by influencing macrophage polarization. Materials and methods Study design This study included both in vitro cell experiments and in vivo animal model experiments to verify the role of Tet1, ARF, and p53 in macrophage polarization and their impact on IPF progression (Fig. 1). Fig. 1Schematic diagram of the proposed scientific hypothesis and mechanism Schematic diagram of the proposed scientific hypothesis and mechanism Cell experiments Cell culture The murine monocyte macrophage cell line RAW264.7 was purchased from ATCC, Cat# TIB-71(by STR profiling) Cell Bank and cultured in high-glucose Dulbecco’s Modified Eagle Medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. The cells were maintained at 37 °C in a 5% CO₂ incubator. Cells were routinely tested for mycoplasma contamination and found to be negative. Cells were passaged every 2–3 days using 0.25% trypsin-EDTA at a split ratio of 1:5, and all experiments were performed with cells between passages 5 and 15. Transfection experiments shRNA and overexpression vectors were designed to target Tet1 and ARF. Transfection was performed using Lipofectamine 3000 reagent. After 48 h, cells were collected for further analysis. Real-time quantitative PCR and Western blot were used to assess the expression changes of Tet1, ARF, and p53. shRNAs targeting Tet1 and ARF were synthesized by [Beijing Kairui Gene Co., Ltd., Beijing, China]. The ARF overexpression plasmid (pCMV-ARF-HA) was purchased from [Beijing Kairui Gene Co., Ltd., Beijing, China, Catalog No. 2436-097]. Transfection was performed using Lipofectamine 3000 reagent, strictly following the manufacturer’s protocol: 2 µg of plasmid or 50 nM shRNA was added per well using a 6-well plate. Animal experiments Experimental animals and model establishment Balb/c mice aged 8–10 weeks were used to establish a bleomycin-induced pulmonary fibrosis model. Dosage: 2.5 milligrams per kilogram. The mice were randomly divided into control and experimental groups, and the model was induced by intratracheal injection of bleomycin. A total of 36 Balb/c mice were used, with 6 mice per group (control, bleomycin model, Tet1 silencing, ARF overexpression, etc.). Experimental detection methods After euthanasia, lung tissue samples were collected and analyzed using hematoxylin and eosin (H&E) staining, Masson’s trichrome staining, and immunohistochemistry to assess the degree of pulmonary fibrosis. Flow cytometry was used to evaluate macrophage polarization in bronchoalveolar lavage fluid (BALF). Markers for identifying M1/M2 macrophages: M1: CD86, iNOS, TLR2; M2: CD206, CD163, Arg1, FIZZ-1. The degree of pulmonary fibrosis was assessed using the Ashcroft scoring system based on H&E and Masson’s trichrome staining. Briefly, each lung section was scored blindly by two independent pathologists on a scale of 0 (normal) to 8 (total fibrosis), and the average score was calculated. Statistical analysis All data were analyzed using GraphPad Prism 8 software. Intergroup comparisons were conducted using the Paired t-test, and results were expressed as mean ± standard deviation. A P-value < 0.05 was considered statistically significant. The biological replicate number n for each experiment is 6. Results Detection of M2 macrophage polarization Flow cytometry was used to analyze changes in M1 and M2 macrophages in BALF, along with the expression of related cytokines. The expression changes of M1 and M2 macrophage markers were further examined using Real-time PCR and Western blot (Fig. 2). Fig. 2Detection of M2 macrophage polarization: (A) Representative flow cytometry plots showing CD206 + M2 macrophages in BALF. (B) Quantitative analysis of M2 macrophage percentage. (C) mRNA expression of M2 markers (Arg1, FIZZ-1) measured by RT-qPCR. (D) Protein levels of M2 markers analyzed by Western blot. Data are presented as mean ± SD (n = 6). *p < 0.05, **p < 0.01, ***p < 0.001 by unpaired t-test. Abbreviations: BALF, bronchoalveolar lavage fluid; Arg1, arginase 1; FIZZ-1, found in inflammatory zone 1 Detection of M2 macrophage polarization: (A) Representative flow cytometry plots showing CD206 + M2 macrophages in BALF. (B) Quantitative analysis of M2 macrophage percentage. (C) mRNA expression of M2 markers (Arg1, FIZZ-1) measured by RT-qPCR. (D) Protein levels of M2 markers analyzed by Western blot. Data are presented as mean ± SD (n = 6). *p < 0.05, **p < 0.01, ***p < 0.001 by unpaired t-test. Abbreviations: BALF, bronchoalveolar lavage fluid; Arg1, arginase 1; FIZZ-1, found in inflammatory zone 1 Effect of Tet1 Silencing on M2 macrophage polarization shRNA targeting Tet1 and its negative control were synthesized. RAW264.7 cells in the logarithmic growth phase were selected for transfection. After 48 h of transfection, follow-up experiments were conducted. Real-time PCR and Western blot were used to analyze the expression changes of Tet1, ARF, p53, M1 macrophage markers (NOS2, TLR2, CD86), and M2 macrophage markers (ARG1, FIZZ-1, CD163). Flow cytometry was also used to assess changes in M1 and M2 macrophages. The results indicate that Tet1 silencing increased ARF mRNA expression by 2.5-fold (p < 0.01) and decreased CD206 + M2 macrophages by 40% (p < 0.05). Tet1 regulates ARF gene expression through DNA methylation, affecting the activation of the p53 pathway (Fig. 3). Fig. 3Effect of Tet1 silencing on M2 macrophage polarization: (A) Representative flow cytometry plots showing CD206 + M2 macrophages in BALF. (B) Quantitative analysis of M2 macrophage percentage. (C) mRNA expression of M2 markers (Arg1, FIZZ-1) measured by RT-qPCR. (D) Protein levels of M2 markers analyzed by Western blot. Data are presented as mean ± SD (n = 6). *p < 0.05, **p < 0.01, ***p < 0.001 by unpaired t-test. Abbreviations: BALF, bronchoalveolar lavage fluid; Arg1, arginase 1; FIZZ-1, found in inflammatory zone 1 Effect of Tet1 silencing on M2 macrophage polarization: (A) Representative flow cytometry plots showing CD206 + M2 macrophages in BALF. (B) Quantitative analysis of M2 macrophage percentage. (C) mRNA expression of M2 markers (Arg1, FIZZ-1) measured by RT-qPCR. (D) Protein levels of M2 markers analyzed by Western blot. Data are presented as mean ± SD (n = 6). *p < 0.05, **p < 0.01, ***p < 0.001 by unpaired t-test. Abbreviations: BALF, bronchoalveolar lavage fluid; Arg1, arginase 1; FIZZ-1, found in inflammatory zone 1 Effect of ARF overexpression on M2 macrophage polarization An increasing number of studies have focused on the genetic factors associated with fibrosis and related complications. Epigenetic modifications, including DNA methylation, serve as a molecular link between environmental factors and various complex diseases, such as inflammation, fibrosis, and cancer. DNA methylation, catalyzed by DNA methyltransferases, primarily results in 5-methylcytosine formation, which is associated with transcriptional silencing of key regulatory genes. Alterations in DNA methylation patterns can induce gene silencing. Previous studies have found that in pulmonary fibrosis, ARF exhibits a hypermethylated state in lung tissues, which correlates with the anti-apoptotic phenotype of fibroblasts. Further bioinformatics analysis has revealed that the ARF promoter contains a CpG island, and in multiple organ cancers, ARF is often downregulated due to hypermethylation. Therefore, we hypothesized that ARF undergoes hypermethylation and is downregulated during the progression of pulmonary fibrosis, leading to enhanced M2 macrophage polarization, which contributes to the onset and progression of pulmonary fibrosis (Fig. 4). Fig. 4Effect of ARF overexpression on M2 macrophage polarization: (A) Representative flow cytometry plots showing CD206 + M2 macrophages in BALF. (B) Quantitative analysis of M2 macrophage percentage. (C) mRNA expression of M2 markers (Arg1, FIZZ-1) measured by RT-qPCR. (D) Protein levels of M2 markers analyzed by Western blot. Data are presented as mean ± SD (n = 6). *p < 0.05, **p < 0.01, ***p < 0.001 by unpaired t-test. Abbreviations: BALF, bronchoalveolar lavage fluid; Arg1, arginase 1; FIZZ-1, found in inflammatory zone 1 Effect of ARF overexpression on M2 macrophage polarization: (A) Representative flow cytometry plots showing CD206 + M2 macrophages in BALF. (B) Quantitative analysis of M2 macrophage percentage. (C) mRNA expression of M2 markers (Arg1, FIZZ-1) measured by RT-qPCR. (D) Protein levels of M2 markers analyzed by Western blot. Data are presented as mean ± SD (n = 6). *p < 0.05, **p < 0.01, ***p < 0.001 by unpaired t-test. Abbreviations: BALF, bronchoalveolar lavage fluid; Arg1, arginase 1; FIZZ-1, found in inflammatory zone 1 In vivo experimental results In the bleomycin-induced pulmonary fibrosis mouse model, Tet1 silencing or ARF overexpression had significant effects on pulmonary histopathological changes. H&E staining and Masson’s trichrome staining demonstrated that these gene expression changes correlated with the severity of pulmonary fibrosis. Immunohistochemical staining was used to detect the expression levels of α-SMA, collagen-1, and collagen-III in lung tissues, which are key markers of fibrosis progression (Fig. 5). Fig. 5Mechanism by which the Tet1/ARF-p53 pathway affects IPF through macrophage polarization: (A) Representative flow cytometry plots showing CD206 + M2 macrophages in BALF. (B) Quantitative analysis of M2 macrophage percentage. (C) mRNA expression of M2 markers (Arg1, FIZZ-1) measured by RT-qPCR. (D) Protein levels of M2 markers analyzed by Western blot. Data are presented as mean ± SD (n = 6). *p < 0.05, **p < 0.01, ***p < 0.001 by unpaired t-test. Abbreviations: BALF, bronchoalveolar lavage fluid; Arg1, arginase 1; FIZZ-1, found in inflammatory zone 1 Mechanism by which the Tet1/ARF-p53 pathway affects IPF through macrophage polarization: (A) Representative flow cytometry plots showing CD206 + M2 macrophages in BALF. (B) Quantitative analysis of M2 macrophage percentage. (C) mRNA expression of M2 markers (Arg1, FIZZ-1) measured by RT-qPCR. (D) Protein levels of M2 markers analyzed by Western blot. Data are presented as mean ± SD (n = 6). *p < 0.05, **p < 0.01, ***p < 0.001 by unpaired t-test. Abbreviations: BALF, bronchoalveolar lavage fluid; Arg1, arginase 1; FIZZ-1, found in inflammatory zone 1 Discussion This study reveals the potential role of the Tet1/ARF-p53 pathway in pulmonary fibrosis. Tet1 regulates the DNA methylation status of the ARF gene, affecting its expression and subsequently activating the p53 signaling pathway. Specifically, Tet1 demethylates the ARF promoter region by converting 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), leading to ARF gene activation. The activation or inhibition of this pathway may influence macrophage polarization, particularly M2 macrophage polarization, thereby impacting the progression of pulmonary fibrosis. Our results are partially consistent with prior studies demonstrating that p53 activation can suppress M2 polarization in tumor-associated macrophages. However, in contrast to a study [14], which reported that p53 promotes fibrosis in alveolar epithelial cells, we observed an anti-fibrotic effect via macrophage modulation. This discrepancy may stem from differences in experimental models (e.g., cell type-specific effects) or disease stages. Our use of a bleomycin-induced model and macrophage-focused approach may explain the distinct outcome. As M2 macrophage polarization is closely associated with fibrosis, the Tet1/ARF-p53 pathway may regulate pulmonary fibrosis by modulating this process. Macrophage polarization plays a critical role in the development of pulmonary fibrosis [15, 16]. Our findings on the Tet1/ARF-p53 pathway should be considered in the context of other well-established fibrotic drivers. For instance, TGF-β is a central mediator of fibroblast activation and extracellular matrix deposition in IPF. It is plausible that the Tet1/ARF-p53 axis intersects with TGF-β signaling, either upstream or downstream, to modulate macrophage polarization and fibrotic responses. Similarly, the Wnt/β-catenin and JAK/STAT pathways have been implicated in IPF pathogenesis. Future studies should explore whether Tet1/ARF-p53 crosstalks with these pathways to coordinately regulate fibrotic progression. M1 macrophages are generally associated with pro-inflammatory responses, while M2 macrophages are linked to anti-inflammatory and tissue repair processes [17–19]. Our study found that Tet1 silencing or ARF overexpression altered M2 macrophage marker expression, suggesting that the Tet1/ARF-p53 pathway may regulate pulmonary fibrosis progression by modulating macrophage polarization. While M2 macrophages are generally pro-fibrotic, our data suggest that the Tet1/ARF/p53 axis may selectively suppress a fibrogenic M2 subset, thereby exerting an anti-fibrotic effect. This discovery provides a new perspective on the immunoregulatory mechanisms of pulmonary fibrosis and may offer potential therapeutic targets. Despite the insights provided by this study into the potential role of the Tet1/ARF-p53 pathway in pulmonary fibrosis, several limitations remain. The data from this study only demonstrate the correlation between Tet1/ARF and p53 and M1/M2 markers, lacking causal evidence for the direct action of p53. The direct role of p53 remains to be further verified by future experimental studies. This study primarily focused on macrophage polarization, whereas pulmonary fibrosis is a complex process involving multiple cell types, including alveolar epithelial cells and fibroblasts. Future research should explore the effects of the Tet1/ARF-p53 pathway on these cell types. Additionally, this study was conducted mainly in cell and animal models, and the mechanistic role and clinical relevance of this pathway in humans require further validation through clinical sample studies. Although ARF and p53 are ubiquitously expressed, our model highlights their specific role in macrophage polarization during pulmonary fibrosis. Future studies should explore their functions in other cell types, such as fibroblasts and alveolar epithelial cells. The findings of this study offer a potential new therapeutic target for pulmonary fibrosis. Modulating the Tet1/ARF-p53 pathway could lead to the development of novel therapeutic strategies aimed at inhibiting or reversing pulmonary fibrosis progression [20–22]. Future studies could investigate small-molecule drugs or gene therapy approaches targeting this pathway to achieve better clinical outcomes. Currently, treatment options for pulmonary fibrosis are limited, primarily relying on anti-inflammatory and anti-fibrotic drugs [23–25]. The discoveries from this study could lay the theoretical foundation for developing new treatment strategies, particularly by targeting macrophage polarization. This could pave the way for more precise therapeutic approaches to improve patient outcomes. In summary, this discussion highlights the Tet1/ARF-p53 pathway as a potential regulatory mechanism in pulmonary fibrosis and underscores its implications for future research and clinical therapeutic strategies. Additionally, this study has the following limitations. First, the use of mouse macrophage cell lines and bleomycin-induced models may not fully replicate the pathophysiological characteristics of human idiopathic pulmonary fibrosis (IPF). Second, the clinical translational potential of interventions targeting this pathway requires further validation using human primary macrophages or clinical samples. Finally, the mechanisms underlying interactions between macrophages and other cell types in the fibrotic microenvironment—such as fibroblasts and epithelial cells—require deeper investigation. Conclusion The study demonstrates that the Tet1/ARF-p53 pathway plays a crucial role in IPF by regulating macrophage polarization. Tet1 influences ARF expression by modifying its methylation status, thereby activating the p53 pathway and inhibiting M2 macrophage polarization, which may mitigate pulmonary fibrosis progression. These findings provide a new potential therapeutic target for IPF. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2 Supplementary Material 3 Supplementary Material 3 Supplementary Material 4 Supplementary Material 4 Supplementary Material 5 Supplementary Material 5 Supplementary Material 6 Supplementary Material 6 Supplementary Material 7 Supplementary Material 7 Supplementary Material 8 Supplementary Material 8 Supplementary Material 9 Supplementary Material 9 Supplementary Material 10 Supplementary Material 10 Supplementary Material 11 Supplementary Material 11 Supplementary Material 12 Supplementary Material 12 Supplementary Material 13 Supplementary Material 13 Supplementary Material 14 Supplementary Material 14 Supplementary Material 15 Supplementary Material 15 Supplementary Material 16 Supplementary Material 16 Supplementary Material 17 Supplementary Material 17 Supplementary Material 18 Supplementary Material 18 Supplementary Material 19 Supplementary Material 19 Supplementary Material 20 Supplementary Material 20 Supplementary Material 21 Supplementary Material 21 Supplementary Material 22 Supplementary Material 22